Jeremy Docken


PDPRA's Operational Challenges

Whether or not the new Prescription Drug Pricing Reduction Act is a good policy, if it is enacted, its proposals have to work as intended and ensure compliant operationalization, writes Jeremy Docken.

Non-compliance Costs Hundreds of Millions in Revenue

A look at the systemic problems resulting from the overlap of MDRP and 340B.